Pergamum AB Product Focus - 2015

1
Pergamum AB Product Pipeline Review - 2015
Published on October - 2015
2
.
Report Overview
About Pergamum ABProduct Pipeline Review
2015 Global Markets Directs, Pergamum AB Product
Pipeline Review - 2015, provides an overview of
the Pergamum AB s pharmaceutical research and
development focus. This report provides
comprehensive information on the current
therapeutic developmental pipeline of Pergamum AB
s complete with comparative analysis at various
stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of
administration (RoA) and molecule type. It also
reviews latest updates, and featured news and
press releases, along with special features on
late-stage and discontinued projects. Global
Markets Directs report features investigational
drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is
built using data and information sourced from
Global Markets Directs proprietary data bases,
Company/University websites, SEC filings,
investor presentations and featured press
releases from company/university sites and
industry-specific third party sources, put
together by Global Markets Directs team. Get
Full Details On http//www.researchbeam.com/perg
amum-ab-product-pipeline-review-2015-market

3
.
Report Overview
Drug profiles/records featured in the report
undergoes periodic updation following a stringent
set of processes that ensures that all the
profiles are updated with the latest set of
information. Additionally, processes including
live news deals tracking, browser based
alert-box and clinical trials registries tracking
ensure that the most recent developments are
captured on a real time basis. The report
enhances decision making capabilities and help to
create effective counter strategies to gain
competitive advantage. It strengthens RD
pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class
products. Note Certain sections in the report
may be removed or altered based on the
availability and relevance of data for the
indicated disease. Scope The report provides
brief overview of Pergamum AB including business
description, key information and facts, and its
locations and subsidiaries The report reviews
current pipeline of Pergamum AB s human
therapeutic division and enlists all their major
and minor projects
4
.
Report Overview
The report features product description and
descriptive mechanism of action for key pipeline
products along with the products developmental
history and major milestones Special feature on
out-licensed and partnered product portfolio The
report summarizes all the dormant and
discontinued pipeline projects Latest company
statement Latest news and deals relating to the
Pergamum ABs pipeline products   Reasons to
buy Evaluate Pergamum ABs strategic position with
total access to detailed information on its
product pipeline Assess the growth potential of
Pergamum AB in its therapy areas of
focus Identify new drug targets and therapeutic
classes in the Pergamum AB s RD portfolio and
develop key strategic initiatives to reinforce
pipeline in those areas Exploit in-licensing
opportunities by identifying windows of
opportunity to fill portfolio gaps
5
Report Overview

• Develop strategic initiatives by understanding
  the focus areas of Pergamum AB and exploit
  collaboration and partnership opportunities
• Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by
  identifying the most promising pipeline of Quest
  Pharma Tech Inc.
• Develop and design in-licensing and out-licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Explore the dormant and discontinued projects of
  Pergamum AB and identify potential opportunities
  in those areas
• Avoid Intellectual Property Rights related issues

6
Table Of Contents
List of Tables 3List of Figures 3Pergamum AB
Snapshot 4Pergamum AB Overview 4Key Information
4Key Facts 4Pergamum AB - Research and
Development Overview 5Key Therapeutic Areas
5Pergamum AB - Pipeline Review 7Pipeline
Products by Stage of Development 7Pipeline
Products - Monotherapy 8Pergamum AB - Pipeline
Products Glance 9Pergamum AB - Clinical Stage
Pipeline Products 9 Phase II Products/Combination
Treatment Modalities 9
7
Table Of Contents
Phase I Products/Combination Treatment Modalities
10Pergamum AB - Early Stage Pipeline Products
11Discovery Products/Combination Treatment
Modalities 11Pergamum AB - Drug Profiles
12DPK-060 12Product Description 12Mechanism of
Action 12RD Progress 12PXL-01 13Product
Description 13Mechanism of Action 13RD
Progress 13LL-37 14Product Description 14
8
Table Of Contents
Mechanism of Action 14RD Progress 14PXL-181
15Product Description 15Mechanism of Action
15RD Progress 15Pergamum AB - Pipeline
Analysis 16Pergamum AB - Pipeline Products by
Route of Administration 16 Enquiry about this
report _at_ http//www.researchbeam.com/pergamum-ab-p
roduct-pipeline-review-2015-market/enquire-about-r
eport
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/pergamum-ab-product-pi
peline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com